The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAscential Regulatory News (ASCL)

Share Price Information for Ascential (ASCL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 314.80
Bid: 313.40
Ask: 314.00
Change: 3.80 (1.22%)
Spread: 0.60 (0.191%)
Open: 315.00
High: 315.00
Low: 309.60
Prev. Close: 311.00
ASCL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed Placing

30 Nov 2016 16:35

RNS Number : 6055Q
BofA Merrill Lynch
30 November 2016
 

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

 

The information contained within this announcement is deemed to constitute inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

PROPOSED PLACING OF APPROXIMATELY 60 MILLION ORDINARY SHARES IN ASCENTIAL PLC ("COMPANY")

30 November 2016

Eden 3 S.à r.l., Eden 4 S.à r.l. and Eden Debtco 2 S.à r.l. (the "Apax Sellers") and Guardian Media Group plc ("GMG" and, together with the Apax Sellers, the "Sellers") announce their intention to sell an aggregate of approximately 60 million ordinary shares (the "Placing Shares") in the capital of the Company. The Apax Sellers are entities indirectly wholly owned by Apax Europe VII.

The Placing Shares represent, in aggregate, approximately 15 per cent of the Company's issued ordinary share capital and constitute approximately 37.7 per cent of the Apax Sellers' combined holdings in the Company and approximately 37.7 per cent of GMG's holding in the Company.  Any remaining shares held by each of the Apax Sellers and GMG will be subject to a lock-up from the date of this announcement until the date which is 90 days after the closing date of the Placing (as defined below) which is expected to be on 5 December 2016, subject to customary exceptions and waiver by the Joint Global Coordinators (as defined below).

The Apax Sellers and GMG have every confidence that the board of directors and management of the Company will continue to execute in line with the Company's stated strategy and manage the Company in the best interests of all shareholders.

The Placing Shares are being offered by way of an accelerated bookbuild (the "Placing"), which will be launched immediately following this announcement. Goldman Sachs International and Merrill Lynch International (together, the "Joint Global Coordinators") are acting as joint global coordinators and Goldman Sachs International, Merrill Lynch International, Deutsche Bank AG and Numis Securities Limited (together, the "Bookrunners") are acting as joint bookrunners in connection with the Placing. The Company will not receive any proceeds from the Placing.

The Placing Shares, in all respects, rank pari passu with the Company's ordinary shares.

The final number of ordinary shares in the capital of the Company to be placed will be agreed by the Bookrunners and the Sellers at the close of the bookbuild process and the results of the Placing will be announced as soon as practicable thereafter. The timings for the close of the bookbuild process, pricing and allocations are at the absolute discretion of the Bookrunners.

The Joint Global Coordinators, in their capacity as joint bookrunners for the placing of ordinary shares in the Company by Eden 3 S.à r.l., Eden 4 S.à r.l. and GMG which completed on 5 September 2016, have consented to the Placing and in doing so have agreed, with respect to the Placing Shares, to waive the lock-up restrictions which otherwise apply to such ordinary shares until 4 December 2016.

 

Important Notice

MEMBERS OF THE GENERAL PUBLIC ARE NOT ELIGIBLE TO TAKE PART IN THE PLACING. THIS ANNOUNCEMENT AND ANY OFFER OF SECURITIES TO WHICH IT RELATES ARE ONLY ADDRESSED TO AND DIRECTED AT (1) IN ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA, PERSONS WHO ARE QUALIFIED INVESTORS WITHIN THE MEANING OF ARTICLE 2(1)(E) OF EU DIRECTIVE 2003/71/EC (AS AMENDED BY DIRECTIVE 2010/73/EU TO THE EXTENT IMPLEMENTED IN THE RELEVANT MEMBER STATE) AND ANY RELEVANT IMPLEMENTING MEASURES (THE "PROSPECTUS DIRECTIVE"); AND (2) IN THE UNITED KINGDOM, PERSONS WHO (I) HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS WHO FALL WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (AS AMENDED) (THE "ORDER"); OR (II) FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER OR (III) ARE PERSONS TO WHOM AN OFFER OF THE PLACING SHARES MAY OTHERWISE LAWFULLY BE MADE (ALL SUCH PERSONS REFERRED TO IN (1) AND (2) TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS"). THE INFORMATION REGARDING THE PLACING SET OUT IN THIS ANNOUNCEMENT MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS.

THIS ANNOUNCEMENT DOES NOT, AND SHALL NOT, IN ANY CIRCUMSTANCES CONSTITUTE A PUBLIC OFFERING, NOR AN OFFER TO SELL OR TO SUBSCRIBE FOR, NOR A SOLICITATION TO OFFER TO PURCHASE OR TO SUBSCRIBE FOR SECURITIES IN ANY JURISDICTION. The distribution of this announcement and the offering or sale of the PLACING SHARES in certain jurisdictions may be restricted by law. No action has been taken by THE APAX SELLERS (OR ANY AFFILIATES THEREOF), APAX PARTNERS LLP ("APAX"), ANY FUNDS ADVISED BY APAX (OR THE GENERAL PARTNER THEREOF) (together, the "APAX FUNDS") OR GMG (OR ANY AFFILIATES THEREOF) or any of the Bookrunners or any of their respective affiliates that would, or which is intended to, permit a public offer of the PLACING SHARES in any jurisdiction or possession or distribution of this announcement or any other offering or publicity material relating to the PLACING SHARES in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required by THE APAX SELLERS, APAX, THE APAX FUNDS, GMG AND any of the Bookrunners to inform themselves about and to observe any applicable restrictions.

WITH RESPECT TO THE MEMBER STATES OF THE EUROPEAN ECONOMIC AREA WHICH HAVE IMPLEMENTED THE PROSPECTUS DIRECTIVE (EACH, A "RELEVANT MEMBER STATE"), NO ACTION HAS BEEN UNDERTAKEN OR WILL BE UNDERTAKEN TO MAKE AN OFFER TO THE PUBLIC OF THE PLACING SHARES SOLD BY THE SELLERS REQUIRING A PUBLICATION OF A PROSPECTUS IN ANY RELEVANT MEMBER STATE. AS A CONSEQUENCE, THE PLACING SHARES MAY ONLY BE OFFERED OR SOLD IN ANY RELEVANT MEMBER STATE PURSUANT TO AN EXEMPTION UNDER THE PROSPECTUS DIRECTIVE.

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OF, OR THE SOLICITATION OF AN OFFER TO ACQUIRE OR DISPOSE OF SECURITIES IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR IN ANY OTHER JURISDICTION IN WHICH SUCH AN OFFER OR SOLICITATION IS UNLAWFUL.

THE PLACING SHARES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE "US SECURITIES ACT"), OR UNDER THE APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN. THE PLACING SHARES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES UNLESS REGISTERED UNDER THE US SECURITIES ACT OR OFFERED IN A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE US SECURITIES ACT AND THE SECURITIES LAWS OF ANY RELEVANT STATE OR OTHER JURISDICTION OF THE UNITED STATES. THERE WILL BE NO PUBLIC OFFERING OF THE PLACING SHARES IN THE UNITED STATES OR ELSEWHERE.

THE PLACING SHARES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE US SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY IN THE UNITED STATES, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THE PLACING OR THE ACCURACY OR ADEQUACY OF THIS ANNOUNCEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES.

No prospectus or offering document has been or will be prepared in connection with the PLACING. Any investment decision to buy securities in the PLACING must be made solely on the basis of publicly available information. Such information is not the responsibility of and has not been independently verified by THE APAX SELLERS (OR AN AFFILIATE THEREOF), APAX, ANY APAX FUND, GMG (OR ANY AFFILIATE THEREOF) or ANY OF the Bookrunners or any of their respective affiliates.

 

GOLDMAN SACHS INTERNATIONAL AND MERRILL LYNCH INTERNATIONAL ARE AUTHORISED BY THE PRUDENTIAL REGULATION AUTHORITY ("PRA") AND REGULATED IN THE UNITED KINGDOM BY THE PRA AND FINANCIAL CONDUCT AUTHORITY. deutsche bank ag, LONDON BRANCH, is authorised under german banking law (competent authority: the european central bank ("ecb")) and, in the united kingdom, by the pra and is subject to supervision by the ecb and by bafin, germany's federal financial supervisory authority, and is subject to limited regulation in the united kingdom by the pra and the fca. numis securities limited is authorised and regulated by the fca. the bookrunners ARE ACTING EXCLUSIVELY FOR THE SELLERS IN CONNECTION WITH THE PLACING AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN THE SELLERS FOR PROVIDING THE PROTECTIONS OFFERED TO THEIR RESPECTIVE CLIENTS, NOR FOR PROVIDING ADVICE IN RELATION TO THE PLACING OR ANY TRANSACTION, MATTER OR ARRANGEMENT REFERRED TO IN THIS ANNOUNCEMENT.

 

In connection with the offering of the placing shares, the Bookrunners or any of their respective affiliates may take up a portion of the placing shares as a principal position and in that capacity may retain, purchase or sell for their own accounts such securities. In addition they may enter into financing arrangements and swaps with investors in connection with which they may from time to time acquire, hold or dispose of the placing shares. They do not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligation to do so.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOELLFFRLSLIVIR
Date   Source Headline
10th Dec 20207:00 amRNSTrading update and segmental restatement
26th Nov 20202:07 pmRNSHolding(s) in Company
16th Nov 202011:42 amRNSHolding(s) in Company
5th Nov 202012:01 pmRNSHolding(s) in Company
22nd Oct 20204:25 pmRNSHolding(s) in Company
7th Oct 20201:02 pmRNSHolding(s) in Company
2nd Oct 20201:37 pmRNSDirector/PDMR Shareholding
1st Oct 20204:53 pmRNSTotal Voting Rights
29th Sep 20207:00 amRNSCOO Appointment
18th Aug 20201:21 pmRNSHolding(s) in Company
12th Aug 20204:33 pmRNSDirector/PDMR Shareholding
4th Aug 20207:00 amRNSMoney20/20 US and Europe 2020 cancellations
31st Jul 202012:10 pmRNSExternal Directorship
27th Jul 20207:05 amRNSAppointment of Non-Executive Director
27th Jul 20207:00 amRNSHalf-year Report
21st Jul 20204:14 pmRNSNotice of Interim Results date
6th Jul 202012:00 pmRNSHolding(s) in Company
6th Jul 202011:59 amRNSHolding(s) in Company
11th Jun 20204:00 pmRNSDirector Declaration
2nd Jun 202011:14 amRNSTotal Voting Rights
18th May 202010:06 amRNSDirector/PDMR Shareholding
7th May 20202:44 pmRNSDirector/PDMR Shareholding
6th May 20201:35 pmRNSResult of AGM
1st May 202011:33 amRNSTotal Voting Rights
29th Apr 20207:00 amRNSCovenant amendments and Q1 trading update
21st Apr 20205:02 pmRNSHolding(s) in Company
20th Apr 20204:38 pmRNSUpdate on 2020 AGM
16th Apr 20205:02 pmRNSHolding(s) in Company
3rd Apr 20202:30 pmRNSHolding(s) in Company
3rd Apr 20207:00 amRNSCannes Lions Cancellation & Other Actions
2nd Apr 20201:00 pmRNSEdge by Ascential launches Market Share 2.0
1st Apr 20205:23 pmRNSTotal Voting Rights
24th Mar 20202:00 pmRNSMoney20/20 Europe deferral to September 2020
18th Mar 20201:00 pmRNSCannes Lions deferral to contingency dates
17th Mar 20207:00 amRNSTransaction in Own Shares
16th Mar 20207:00 amRNSTransaction in Own Shares
13th Mar 20209:37 amRNSHolding(s) in Company
12th Mar 20205:51 pmRNSTransaction in Own Shares
11th Mar 20205:26 pmRNSTransaction in Own Shares
11th Mar 202012:00 pmRNSContingency Dates - Cannes Lions & Money20/20 Eu
10th Mar 20205:39 pmRNSTransaction in Own Shares
9th Mar 20205:21 pmRNSTransaction in Own Shares
6th Mar 20204:57 pmRNSTransaction in Own Shares
5th Mar 20205:04 pmRNSTransaction in Own Shares
4th Mar 20205:32 pmRNSTransaction in Own Shares
3rd Mar 20204:42 pmRNSTransaction in Own Shares
3rd Mar 20207:00 amRNSTransaction in Own Shares
28th Feb 20204:44 pmRNSTransaction in Own Shares
27th Feb 20205:48 pmRNSDirector/PDMR Shareholding
27th Feb 20205:46 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.